{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:53:39Z","timestamp":1780102419240,"version":"3.54.0"},"reference-count":134,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009210","name":"Food and Drug Administration","doi-asserted-by":"publisher","award":["R01FD006030"],"award-info":[{"award-number":["R01FD006030"]}],"id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Sickle cell disease (SCD) afflicts millions of people worldwide but is referred to as an orphan disease in the United States. Over the past several decades, there has been an increasing understanding of the pathophysiology of SCD and its complications. While most individuals with SCD in resource-rich countries survive into adulthood, the life expectancy of patients with SCD remains substantially shorter than for the general African-American population. SCD can be cured using hematopoietic stem cell transplantation and possibly gene therapy, but these treatment approaches are not available to most patients, the majority of whom reside in low- and middle-income countries. Until relatively recently, only one drug, hydroxyurea, was approved by the US Food and Drug Administration to ameliorate disease severity. Multiple other drugs (L-glutamine, crizanlizumab, and voxelotor) have recently been approved for the treatment of SCD, with several others at various stages of clinical testing. The availability of multiple agents to treat SCD raises questions related to the choice of appropriate drug therapy, combination of multiple agents, and affordability of recently approved products. The enthusiasm for new drug development provides opportunities to involve patients in low- and middle-income nations in the testing of potentially disease-modifying therapies and has the potential to contribute to capacity building in these environments. Demonstration that these agents, alone or in combination, can prevent or decrease end-organ damage would provide additional evidence for the role of drug therapies in improving outcomes in SCD.<\/ns4:p>","DOI":"10.12688\/f1000research.22433.1","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T14:39:56Z","timestamp":1591886396000},"page":"592","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Drug Therapies for the Management of Sickle Cell Disease"],"prefix":"10.12688","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5770-7280","authenticated-orcid":false,"given":"Parul","family":"Rai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4501-9982","authenticated-orcid":false,"given":"Kenneth I.","family":"Ataga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"e1001484","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010-2050: Modelling based on demographics, excess mortality, and interventions.","volume":"10","author":"F Piel","year":"2013","journal-title":"PLoS Med."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"S398-405","DOI":"10.1016\/j.amepre.2011.09.013","article-title":"Sickle cell disease in Africa: A neglected cause of early childhood mortality.","volume":"41","author":"S Grosse","year":"2011","journal-title":"Am J Prev Med."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"905-12","DOI":"10.3324\/haematol.10937","article-title":"Clinical outcomes in children with sickle cell disease living in England: A neonatal cohort in East London.","volume":"92","author":"P Telfer","year":"2007","journal-title":"Haematologica."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"3447-52","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease.","volume":"115","author":"C Quinn","year":"2010","journal-title":"Blood."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"927-37","DOI":"10.1111\/bjh.14015","article-title":"Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: Impact of national guidelines.","volume":"173","author":"N Couque","year":"2016","journal-title":"Br J Haematol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"530-5","DOI":"10.1002\/ajh.23683","article-title":"Factors associated with survival in a contemporary adult sickle cell disease cohort.","volume":"89","author":"H Elmariah","year":"2014","journal-title":"Am J Hematol."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1436-8","DOI":"10.1182\/blood-2016-05-716910","article-title":"Survival in adults with sickle cell disease in a high-income setting.","volume":"128","author":"K Gardner","year":"2016","journal-title":"Blood."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"626-36","DOI":"10.3324\/haematol.2016.153791","article-title":"Risk factors for mortality in adult patients with sickle cell disease: A meta-analysis of studies in North America and Europe.","volume":"102","author":"P Maitra","year":"2017","journal-title":"Haematologica."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"615-7","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: A pooled analysis.","volume":"133","author":"M DeBaun","year":"2019","journal-title":"Blood."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1171-85","DOI":"10.1016\/j.hoc.2014.08.014","article-title":"Hematopoietic stem cell transplantation for patients with sickle cell disease: Progress and future directions.","volume":"28","author":"C Fitzhugh","year":"2014","journal-title":"Hematol Oncol Clin of North Am."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"848-55","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene Therapy in a Patient with Sickle Cell Disease.","volume":"376","author":"J Ribeil","year":"2017","journal-title":"N Engl J Med."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"762-9","DOI":"10.1056\/NEJM199709113371107","article-title":"Pathogenesis and Treatment of Sickle Cell Disease.","volume":"337","author":"F Epstein","year":"1997","journal-title":"N Engl J Med."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"2018-31","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease.","volume":"376","author":"D Rees","year":"2010","journal-title":"Lancet."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"20-7","DOI":"10.1111\/j.1365-2567.2012.03612.x","article-title":"Turned on by danger: Activation of CD1d-restricted invariant natural killer T cells.","volume":"137","author":"V Lawson","year":"2012","journal-title":"Immunology."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"1383-9","DOI":"10.1038\/nm1202-799","article-title":"Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.","volume":"8","author":"C Reiter","year":"2002","journal-title":"Nat Med."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"2753-8","DOI":"10.1182\/blood.V78.10.2753.bloodjournal78102753","article-title":"Hydroxyl radical formation by sickle erythrocyte membranes: Role of pathologic iron deposits and cytoplasmic reducing agents.","volume":"78","author":"T Repka","year":"1991","journal-title":"Blood."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"60-8","DOI":"10.1172\/JCI118074","article-title":"Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.","volume":"96","author":"R de Caterina","year":"1995","journal-title":"J Clin Invest."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"664-6","DOI":"10.1038\/333664a0","article-title":"Vascular endothelial cells synthesize nitric oxide from L-arginine.","volume":"333","author":"R Palmer","year":"1988","journal-title":"Nature."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"37-47","DOI":"10.1016\/j.blre.2006.07.001","article-title":"Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes.","volume":"21","author":"G Kato","year":"2007","journal-title":"Blood Rev."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"362-9","DOI":"10.1182\/asheducation-2013.1.362","article-title":"Vaso-occlusion in sickle cell disease: Pathophysiology and novel targeted therapies.","volume":"2013","author":"D Manwani","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"245-56","DOI":"10.1016\/j.blre.2015.12.003","article-title":"Coagulation Abnormalities of Sickle Cell Disease: Relationship With Clinical Outcomes and the Effect of Disease Modifying Therapies.","volume":"30","author":"D Noubouossie","year":"2016","journal-title":"Blood Rev."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease.","volume":"4","author":"G Kato","year":"2018","journal-title":"Nat Rev Dis Primers."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"1317-22","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.","volume":"332","author":"S Charache","year":"1995","journal-title":"N Engl J Med."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"2719-26","DOI":"10.1182\/blood-2017-02-765891","article-title":"Treating sickle cell disease by targeting HbS polymerization.","volume":"129","author":"W Eaton","year":"2017","journal-title":"Blood."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"1639-44","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in Sickle Cell Disease. Life Expectancy and Risk Factors for Early Death.","volume":"330","author":"O Platt","year":"1994","journal-title":"N Engl J Med."},{"key":"ref-29","doi-asserted-by":"crossref","first-page":"643-9","DOI":"10.1182\/blood.V84.2.643.643","article-title":"The acute chest syndrome in sickle cell disease: Incidence and risk factors. The Cooperative Study of Sickle Cell Disease.","volume":"84","author":"O Castro","year":"1994","journal-title":"Blood."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"1057-72","DOI":"10.1016\/j.exphem.2008.06.014","article-title":"A Cell Stress Signaling Model of Fetal Hemoglobin Induction: What Doesn't Kill Red Blood Cells May Make Them Stronger.","volume":"36","author":"R Mabaera","year":"2008","journal-title":"Exp Hematol."},{"key":"ref-31","first-page":"273-9","article-title":"Iron chelators hydroxyurea and bathophenanthroline disulfonate inhibit DNA synthesis by different pathways.","volume":"34","author":"F Alca\u00edn","year":"1994","journal-title":"Biochem Mol Biol Int."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"231-9","DOI":"10.1172\/JCI16672","article-title":"Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase.","volume":"111","author":"V Cokic","year":"2003","journal-title":"J Clin Invest."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"1675-81","DOI":"10.1016\/j.freeradbiomed.2006.01.002","article-title":"Rat liver-mediated metabolism of hydroxyurea to nitric oxide.","volume":"40","author":"J Huang","year":"2006","journal-title":"Free Radic Biol Med."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"158-65","DOI":"10.1097\/MOH.0b013e32834521dd","article-title":"Hydroxyurea for sickle cell anemia: What have we learned and what questions still remain?","volume":"18","author":"P McGann","year":"2011","journal-title":"Curr Opin Hematol."},{"key":"ref-35","doi-asserted-by":"crossref","first-page":"4701-10","DOI":"10.1182\/blood.V88.12.4701.bloodjournal88124701","article-title":"A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy.","volume":"88","author":"K Bridges","year":"1996","journal-title":"Blood."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"322-7","DOI":"10.1046\/j.1365-2141.2000.02040.x","article-title":"Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin.","volume":"109","author":"C Hillery","year":"2000","journal-title":"Br J Haematol."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"502-10","DOI":"10.3324\/haematol.12070","article-title":"Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease.","volume":"93","author":"M Odievre","year":"2008","journal-title":"Haematologica."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"534-42","DOI":"10.3324\/haematol.2010.026740","article-title":"Differential modulation of adhesion molecule expression by hydroxycarbamide in human endothelial cells from the micro- and macrocirculation: Potential implications in sickle cell disease vasoocclusive events.","volume":"96","author":"S Laurance","year":"2011","journal-title":"Haematologica."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"436-44","DOI":"10.1046\/j.1365-2141.2002.03274.x","article-title":"Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease.","volume":"116","author":"M Gladwin","year":"2002","journal-title":"Br J Haematol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"1006-10","DOI":"10.1124\/mol.55.6.1006","article-title":"Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea.","volume":"55","author":"R Glover","year":"1999","journal-title":"Mol Pharmacol."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"1663-72","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BABY HUG).","volume":"377","author":"W Wang","year":"2011","journal-title":"Lancet."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"1017-23","DOI":"10.1002\/pbc.25391","article-title":"Low and Fixed Dose of Hydroxyurea Is Effective and Safe in Patients With HbS\u03b2(+) Thalassemia With IVS1-5(G\u2192C) Mutation.","volume":"62","author":"S Dehury","year":"2015","journal-title":"Pediatr Blood Cancer."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"929-33","DOI":"10.1007\/s13312-013-0264-0","article-title":"Efficacy of Fixed Low Dose Hydroxyurea in Indian Children With Sickle Cell Anemia: A Single Centre Experience.","volume":"50","author":"D Jain","year":"2013","journal-title":"Indian Pediatr."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"661-70","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide Versus Chronic Transfusion for Maintenance of Transcranial Doppler Flow Velocities in Children With Sickle Cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Multicentre, Open-Label, Phase 3, Non-Inferiority Trial.","volume":"387","author":"R Ware","year":"2016","journal-title":"Lancet."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"1847-53","DOI":"10.1681\/ASN.2014111126","article-title":"Six Months of Hydroxyurea Reduces Albuminuria in Patients With Sickle Cell Disease.","volume":"27","author":"P Bartolucci","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"852-60","DOI":"10.1111\/bjh.12323","article-title":"The Effect of Hydroxcarbamide Therapy on Survival of Children With Sickle Cell Disease.","volume":"161","author":"C Lobo","year":"2013","journal-title":"Br J Haematol."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"1645-51","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment.","volume":"289","author":"M Steinberg","year":"2003","journal-title":"JAMA."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"403-8","DOI":"10.1002\/ajh.21699","article-title":"The Risks and Benefits of Long-Term Use of Hydroxyurea in Sickle Cell Anemia: A 17.5 Year Follow-Up.","volume":"85","author":"M Steinberg","year":"2010","journal-title":"Am J Hematol."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"2354-63","DOI":"10.1182\/blood-2009-05-221333","article-title":"The Effect of Prolonged Administration of Hydroxyurea on Morbidity and Mortality in Adult Patients With Sickle Cell Syndromes: Results of a 17-year, Single-Center Trial (LaSHS).","volume":"115","author":"E Voskaridou","year":"2010","journal-title":"Blood."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"436-43","DOI":"10.1182\/asheducation-2015.1.436","article-title":"Optimizing Hydroxyurea Therapy for Sickle Cell Anemia.","volume":"2015","author":"R Ware","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"871-9","DOI":"10.1002\/ajh.25510","article-title":"Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.","volume":"94","author":"P McGann","year":"2019","journal-title":"Am J Hematol."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"1333-9","DOI":"10.1002\/ajh.24906","article-title":"A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.","volume":"92","author":"J Estepp","year":"2017","journal-title":"Am J Hematol."},{"key":"ref-53","article-title":"Hydroxyurea Optimization Through Precision Study (HOPS).","year":"2020","journal-title":"Clinical Trials."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3390\/jcm8101701","article-title":"Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach.","volume":"8","author":"C Nazon","year":"2019","journal-title":"J Clin Med."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"126-9","DOI":"10.1111\/j.1365-2141.2008.07027.x","article-title":"Clinical effectiveness of decitabine in severe sickle cell disease.","volume":"141","author":"Y Saunthararajah","year":"2008","journal-title":"Br J Haematol."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"e1002382","DOI":"10.1371\/journal.pmed.1002382","article-title":"Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.","volume":"14","author":"R Molokie","year":"2017","journal-title":"PLoS Med."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"1790-7","DOI":"10.1182\/blood.V93.6.1790.406k27_1790_1797","article-title":"Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease.","volume":"93","author":"G Atweh","year":"1999","journal-title":"Blood."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"2483-90","DOI":"10.1182\/blood-2009-02-204990","article-title":"The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice.","volume":"115","author":"R Hebbel","year":"2010","journal-title":"Blood."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"87-99","DOI":"10.1111\/j.1749-6632.1998.tb10466.x","article-title":"Cellular and Molecular Effects of a Pulse Butyrate Regimen and New Inducers of Globin Gene Expression and Hematopoiesis.","volume":"850","author":"T Ikuta","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"1017-21","DOI":"10.1002\/ajh.23306","article-title":"A phase 1\/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.","volume":"87","author":"A Kutlar","year":"2012","journal-title":"Am J Hematol."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"E255-E260","DOI":"10.1002\/ajh.23533","article-title":"A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.","volume":"88","author":"A Kutlar","year":"2013","journal-title":"Am J Hematol."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"3668-9","DOI":"10.1182\/blood-2015-03-635391","article-title":"Phase 1\/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea.","volume":"125","author":"M Okam","year":"2015","journal-title":"Blood."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"709-13","DOI":"10.1002\/ajh.23725","article-title":"A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.","volume":"89","author":"M Reid","year":"2014","journal-title":"Am J Hematol."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"e0153767","DOI":"10.1371\/journal.pone.0153767","article-title":"Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2.","volume":"11","author":"J Shearstone","year":"2016","journal-title":"PLoS One."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"546-553.e3","DOI":"10.1016\/j.exphem.2015.04.005","article-title":"RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases \u03b3-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model.","volume":"43","author":"A Rivers","year":"2015","journal-title":"Exp Hematol."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"386-96","DOI":"10.1182\/blood-2015-02-626259","article-title":"The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice.","volume":"126","author":"S Cui","year":"2015","journal-title":"Blood."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"60-64.e2","DOI":"10.1016\/j.exphem.2018.08.003","article-title":"Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons.","volume":"67","author":"A Rivers","year":"2018","journal-title":"Exp Hematol."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"1109-12","DOI":"10.1182\/blood-2010-11-319137","article-title":"Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice.","volume":"118","author":"S Meiler","year":"2011","journal-title":"Blood."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/blood.V122.21.777.777","article-title":"Pomalidomide In Sickle Cell Disease: Phase I Study Of a Novel Anti-Switching Agent.","volume":"122","author":"A Kutlar","year":"2013","journal-title":"Blood."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"321-33","DOI":"10.1182\/blood-2017-11-814335","article-title":"Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cells.","volume":"132","author":"Y Zhang","year":"2018","journal-title":"Blood."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"e96409","DOI":"10.1172\/jci.insight.96409","article-title":"Dimethyl fumarate increases fetal hemoglobin, provides heme detoxification, and corrects anemia in sickle cell disease.","volume":"2","author":"S Krishnamoorthy","year":"2017","journal-title":"JCI Insight."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"1177-1186","DOI":"10.1002\/ajh.24879","article-title":"SIRT1 activates the expression of fetal hemoglobin genes.","volume":"92","author":"Y Dai","year":"2017","journal-title":"Am J Hematol."},{"key":"ref-73","doi-asserted-by":"publisher","first-page":"141-53","DOI":"10.1111\/bjh.14214","article-title":"GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.","volume":"175","author":"D Oksenberg","year":"2016","journal-title":"Br J Haematol."},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"1865-1875","DOI":"10.1182\/blood-2018-08-868893","article-title":"A phase 1\/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.","volume":"133","author":"J Howard","year":"2019","journal-title":"Blood."},{"key":"ref-75","doi-asserted-by":"publisher","first-page":"95-105","DOI":"10.3233\/CH-170340","article-title":"GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions.","volume":"70","author":"K Dufu","year":"2018","journal-title":"Clin Hemorheol Microcirc."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"509-519","DOI":"10.1056\/NEJMoa1903212","article-title":"A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.","volume":"381","author":"E Vichinsky","year":"2019","journal-title":"N Engl J Med."},{"key":"ref-77","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.V122.21.1009.1009","article-title":"Phase 1 Clinical Trial Of The Candidate Anti-Sickling Agent Aes-103 In Adults With Sickle Cell Anemia.","volume":"122","author":"G Kato","year":"2013","journal-title":"Blood."},{"key":"ref-78","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2019-121889","article-title":"Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects.","volume":"134","author":"T Kalfa","year":"2019","journal-title":"Blood."},{"key":"ref-79","doi-asserted-by":"publisher","first-page":"2757-64","DOI":"10.1182\/blood-2013-02-486282","article-title":"MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice.","volume":"122","author":"J Belcher","year":"2013","journal-title":"Blood."},{"key":"ref-80","doi-asserted-by":"publisher","first-page":"346-350","DOI":"10.1111\/aor.12934","article-title":"SANGUINATE (PEGylated Carboxyhemoglobin Bovine): Mechanism of Action and Clinical Update.","volume":"41","author":"A Abuchowski","year":"2017","journal-title":"Artif Organs."},{"key":"ref-81","doi-asserted-by":"publisher","first-page":"23-29","DOI":"10.1007\/978-3-319-38810-6_3","article-title":"Clinical Evaluation of MP4CO: A Phase 1b Escalating-Dose, Safety and Tolerability Study in Stable Adult Patients with Sickle Cell Disease.","volume":"923","author":"P Keipert","year":"2016","journal-title":"Adv Exp Med Biol."},{"key":"ref-82","doi-asserted-by":"publisher","first-page":"20-27","DOI":"10.1016\/j.bjhh.2016.08.004","article-title":"A Phase Ib open label, randomized, safety study of SANGUINATE\u2122 in patients with sickle cell anemia.","volume":"39","author":"H Misra","year":"2017","journal-title":"Rev Bras Hematol Hemoter."},{"key":"ref-83","doi-asserted-by":"publisher","first-page":"238-40","DOI":"10.1038\/275238a0","article-title":"Requirement for therapeutic inhibition of sickle haemoglobin gelation.","volume":"275","author":"H Sunshine","year":"1978","journal-title":"Nature."},{"key":"ref-84","doi-asserted-by":"publisher","first-page":"92-104","DOI":"10.1111\/j.1365-2141.2010.08520.x","article-title":"Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: A phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).","volume":"153","author":"K Ataga","year":"2011","journal-title":"Br J Haematol."},{"key":"ref-85","doi-asserted-by":"publisher","first-page":"3991-7","DOI":"10.1182\/blood-2007-08-110098","article-title":"Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.","volume":"111","author":"K Ataga","year":"2008","journal-title":"Blood."},{"key":"ref-86","doi-asserted-by":"publisher","first-page":"1651-7","DOI":"10.1182\/blood-2015-05-647107","article-title":"A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children.","volume":"126","author":"D Brousseau","year":"2015","journal-title":"Blood."},{"key":"ref-87","doi-asserted-by":"publisher","first-page":"e1634-41","DOI":"10.1542\/peds.2013-2065","article-title":"Intravenous magnesium sulfate for vaso-occlusive episodes in sickle cell disease.","volume":"132","author":"R Goldman","year":"2013","journal-title":"Pediatrics."},{"key":"ref-88","doi-asserted-by":"publisher","first-page":"284-9","DOI":"10.1046\/j.1365-2141.2000.01861.x","article-title":"Oral magnesium pidolate: Effects of long-term administration in patients with sickle cell disease.","volume":"108","author":"L de Franceschi","year":"2000","journal-title":"Br J Haematol."},{"key":"ref-89","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood.V128.22.121.121","article-title":"SCD-101: A New Anti-Sickling Drug Reduces Pain and Fatigue and Improves Red Blood Cell Shape in Peripheral Blood of Patients with Sickle Cell Disease.","volume":"128","author":"R Swift","year":"2016","journal-title":"Blood."},{"key":"ref-90","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1056\/NEJMc1811050","article-title":"A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.","volume":"379","author":"Y Niihara","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-91","doi-asserted-by":"publisher","first-page":"1097-105","DOI":"10.1007\/s00277-011-1404-z","article-title":"N-acetylcysteine reduces oxidative stress in sickle cell patients.","volume":"91","author":"E Nur","year":"2012","journal-title":"Ann Hematol."},{"key":"ref-92","doi-asserted-by":"publisher","first-page":"444-8","DOI":"10.1111\/bjh.14809","article-title":"Effect of N-acetylcysteine on pain in daily life in patients with sickle cell disease: A randomised clinical trial.","volume":"182","author":"J Sins","year":"2018","journal-title":"Br J Haematol."},{"key":"ref-93","doi-asserted-by":"publisher","first-page":"429-39","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.","volume":"376","author":"K Ataga","year":"2017","journal-title":"N Engl J Med."},{"key":"ref-94","doi-asserted-by":"publisher","first-page":"2099-106","DOI":"10.1001\/jama.286.17.2099","article-title":"Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial.","volume":"286","author":"E Orringer","year":"2001","journal-title":"JAMA."},{"key":"ref-96","doi-asserted-by":"publisher","first-page":"1779-86","DOI":"10.1182\/blood-2009-12-260513","article-title":"GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.","volume":"116","author":"J Chang","year":"2010","journal-title":"Blood."},{"key":"ref-97","doi-asserted-by":"publisher","first-page":"2656-64","DOI":"10.1182\/blood-2014-06-583351","article-title":"Randomized phase 2 study of GMI-1070 in SCD: Reduction in time to resolution of vaso-occlusive events and decreased opioid use.","volume":"125","author":"M Telen","year":"2015","journal-title":"Blood."},{"key":"ref-99","doi-asserted-by":"publisher","first-page":"3790-6","DOI":"10.1182\/blood-2002-02-0626","article-title":"Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin.","volume":"100","author":"N Matsui","year":"2002","journal-title":"Blood."},{"key":"ref-100","doi-asserted-by":"publisher","first-page":"3378-85","DOI":"10.1182\/blood-2004-02-0713","article-title":"The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo.","volume":"104","author":"S Embury","year":"2004","journal-title":"Blood."},{"key":"ref-101","doi-asserted-by":"publisher","first-page":"392-6","DOI":"10.1160\/Th06-12-0718","article-title":"Reduction of Painful Vaso-occlusive Crisis of Sickle Cell Anaemia by Tinzaparin in a Double-blind Randomized Trial.","volume":"98","author":"M Qari","year":"2017","journal-title":"Thromb Haemost."},{"key":"ref-102","doi-asserted-by":"publisher","first-page":"935-48","DOI":"10.1111\/bjh.14303","article-title":"Sevuparin Binds to Multiple Adhesive Ligands and Reduces Sickle Red Blood Cell-induced Vaso-occlusion.","volume":"175","author":"M Telen","year":"2016","journal-title":"Br J Haematol."},{"key":"ref-103","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1182\/blood-2019-124653","article-title":"Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01).","volume":"134","author":"B Biemond","year":"2019","journal-title":"Blood."},{"key":"ref-104","doi-asserted-by":"publisher","first-page":"1057-66","DOI":"10.1161\/CIRCRESAHA.112.266411","article-title":"Intravenous immunoglobulins modulate neutrophil activation and vascular injury through Fc\u03b3RIII and SHP-1.","volume":"110","author":"J Jang","year":"2012","journal-title":"Circ Res."},{"key":"ref-105","doi-asserted-by":"publisher","first-page":"381-5","DOI":"10.1002\/ajh.23956","article-title":"Single-dose Intravenous Gammaglobulin Can Stabilize Neutrophil Mac-1 Activation in Sickle Cell Pain Crisis.","volume":"90","author":"D Manwani","year":"2015","journal-title":"Am J Hematol."},{"key":"ref-106","doi-asserted-by":"publisher","first-page":"733-7","DOI":"10.1056\/NEJM199403173301101","article-title":"High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease.","volume":"330","author":"T Griffin","year":"1994","journal-title":"N Engl J Med."},{"key":"ref-107","doi-asserted-by":"publisher","first-page":"3082-9","DOI":"10.1182\/blood.V92.9.3082","article-title":"Beneficial Effect of Intravenous Dexamethasone in Children With Mild to Moderately Severe Acute Chest Syndrome Complicating Sickle Cell Disease.","volume":"92","author":"J Bernini","year":"1998","journal-title":"Blood."},{"key":"ref-108","doi-asserted-by":"publisher","first-page":"55-62","DOI":"10.1016\/j.bcmd.2018.03.001","article-title":"Early Initiation of Inhaled Corticosteroids does not Decrease Acute Chest Syndrome Morbidity in Pediatric Patients with Sickle Cell Disease.","volume":"71","author":"A Leonard","year":"2018","journal-title":"Blood Cells Mol Dis."},{"key":"ref-109","doi-asserted-by":"publisher","first-page":"622-31","DOI":"10.1002\/ajh.24742","article-title":"Inhaled Steroids Reduce Pain and sVCAM Levels in Individuals with Sickle Cell Disease: A Triple-blind, Randomized trial.","volume":"92","author":"J Glassberg","year":"2017","journal-title":"Am J Hematol."},{"key":"ref-110","doi-asserted-by":"publisher","first-page":"5010-20","DOI":"10.1182\/blood-2010-06-290643","article-title":"Adenosine A2A Receptors Induced on iNKT and NK Cells Reduce Pulmonary Inflammation and Injury in Mice with Sickle Cell Disease.","volume":"116","author":"K Wallace","year":"2010","journal-title":"Blood."},{"key":"ref-111","doi-asserted-by":"publisher","first-page":"3329-34","DOI":"10.1182\/blood-2012-11-465963","article-title":"Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson.","volume":"121","author":"J Field","year":"2013","journal-title":"Blood."},{"key":"ref-112","doi-asserted-by":"publisher","first-page":"1645-9","DOI":"10.1182\/bloodadvances.2017009613","article-title":"Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease.","volume":"1","author":"J Field","year":"2017","journal-title":"Blood Adv."},{"key":"ref-113","doi-asserted-by":"publisher","first-page":"e0171067","DOI":"10.1371\/journal.pone.0171067","article-title":"NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease.","volume":"12","author":"J Field","year":"2017","journal-title":"PLoS One."},{"key":"ref-114","doi-asserted-by":"publisher","first-page":"655-63","DOI":"10.1111\/j.1365-2141.2010.08480.x","article-title":"A pilot study of the short-term use of simvastatin in sickle cell disease: Effects on markers of vascular dysfunction.","volume":"153","author":"C Hoppe","year":"2011","journal-title":"Br J Haematol."},{"key":"ref-115","doi-asserted-by":"publisher","first-page":"620-9","DOI":"10.1111\/bjh.14580","article-title":"Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: A pilot efficacy trial.","volume":"177","author":"C Hoppe","year":"2017","journal-title":"Br J Haematol."},{"key":"ref-116","doi-asserted-by":"publisher","first-page":"E299-E301","DOI":"10.1002\/ajh.25614","article-title":"A pilot study of the effect of atorvastatin on endothelial function and albuminuria in sickle cell disease.","volume":"94","author":"K Ataga","year":"2019","journal-title":"Am J Hematol."},{"key":"ref-117","doi-asserted-by":"publisher","first-page":"37-44","DOI":"10.3945\/ajcn.112.036319","article-title":"Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: Randomized, double-blind, placebo-controlled trial.","volume":"97","author":"A Daak","year":"2013","journal-title":"Am J Clin Nutr."},{"key":"ref-118","doi-asserted-by":"publisher","first-page":"1969-79","DOI":"10.1182\/bloodadvances.2018021444","article-title":"Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial).","volume":"2","author":"A Daak","year":"2018","journal-title":"Blood Adv."},{"key":"ref-119","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood-2019-123355","article-title":"Double-Blind, Randomized Study of Canakinumab Treatment in Pediatric and Young Adult Patients with Sickle Cell Anemia.","volume":"134","author":"D Rees","year":"2019","journal-title":"Blood."},{"key":"ref-120","doi-asserted-by":"publisher","first-page":"4125-33","DOI":"10.1182\/blood-2010-08-301366","article-title":"Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S.","volume":"117","author":"F Gavins","year":"2011","journal-title":"Blood."},{"key":"ref-121","doi-asserted-by":"publisher","first-page":"636-46","DOI":"10.1182\/blood-2012-04-424143","article-title":"Tissue Factor Promotes Activation of Coagulation and Inflammation in a Mouse Model of Sickle Cell Disease.","volume":"120","author":"P Chantrathammachart","year":"2012","journal-title":"Blood."},{"key":"ref-122","doi-asserted-by":"publisher","first-page":"1844-55","DOI":"10.1182\/blood-2015-01-625707","article-title":"Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice.","volume":"126","author":"P Arumugam","year":"2015","journal-title":"Blood."},{"key":"ref-123","doi-asserted-by":"publisher","first-page":"91-6","DOI":"10.1182\/asheducation-2007.1.91","article-title":"Hypercoagulability in Sickle Cell Disease: New Approaches to an Old Problem.","volume":"2007","author":"K Ataga","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"ref-124","doi-asserted-by":"publisher","first-page":"355-74","DOI":"10.1016\/j.hoc.2013.11.011","article-title":"Role of the Hemostatic System on Sickle Cell Disease Pathophysiology and Potential Therapeutics.","volume":"28","author":"Z Pakbaz","year":"2014","journal-title":"Hematol Oncol Clin North Am."},{"key":"ref-125","doi-asserted-by":"publisher","first-page":"781-4","DOI":"10.1016\/s0022-3476(83)80258-3","article-title":"Trial of Low Doses of Aspirin as Prophylaxis in Sickle Cell Disease.","volume":"102","author":"J Greenberg","year":"1983","journal-title":"J Pediatr."},{"key":"ref-126","doi-asserted-by":"publisher","first-page":"102-7","DOI":"10.1159\/000207105","article-title":"Therapeutic effect of aspirin in sickle cell anaemia.","volume":"66","author":"N Osamo","year":"1981","journal-title":"Acta Haematol."},{"key":"ref-127","doi-asserted-by":"publisher","first-page":"61-4","DOI":"10.1159\/000206360","article-title":"Treatment of Sickle Cell Diseases With Aspirin.","volume":"72","author":"M Zago","year":"1984","journal-title":"Acta Haematol."},{"key":"ref-128","doi-asserted-by":"publisher","first-page":"341-5","DOI":"10.1016\/j.thromres.2013.08.002","article-title":"A Pilot Study of Eptifibatide for Treatment of Acute Pain Episodes in Sickle Cell Disease.","volume":"132","author":"P Desai","year":"2013","journal-title":"Thromb Res."},{"key":"ref-129","first-page":"199-212","article-title":"Clinical and Biological Double-Blind-Study of Ticlopidine in Preventive Treatment of Sickle-Cell Disease Crises.","volume":"15","author":"R Cabannes","year":"1984","journal-title":"Agents Actions Suppl."},{"key":"ref-130","doi-asserted-by":"publisher","first-page":"625-35","DOI":"10.1056\/NEJMoa1512021","article-title":"A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.","volume":"374","author":"M Heeney","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-131","doi-asserted-by":"publisher","first-page":"1493-500","DOI":"10.1002\/ajh.25273","article-title":"A Dose-Ranging Study of Ticagrelor in Children Aged 3-17 Years With Sickle Cell Disease: A 2-part Phase 2 Study.","volume":"93","author":"L Hsu","year":"2018","journal-title":"Am J Hematol."},{"key":"ref-132","doi-asserted-by":"publisher","first-page":"269-78","DOI":"10.1111\/bjh.15646","article-title":"Ticagrelor Does Not Impact Patient-Reported Pain in Young Adults With Sickle Cell Disease: A Multicentre, Randomised Phase IIb Study.","volume":"184","author":"J Kanter","year":"2019","journal-title":"Br J Haematol."},{"key":"ref-133","doi-asserted-by":"publisher","first-page":"105835","DOI":"10.1016\/j.cct.2019.105835","article-title":"Ticagrelor Versus Placebo for the Reduction of Vaso-Occlusive Crises in Pediatric Sickle Cell Disease: Rationale and Design of a Randomized, Double-Blind, Parallel-Group, Multicenter Phase 3 Study (HESTIA3).","volume":"85","author":"M Heeney","year":"2019","journal-title":"Contemp Clin Trials."},{"key":"ref-134","doi-asserted-by":"publisher","first-page":"750-60","DOI":"10.1172\/JCI89741","article-title":"Intravascular Hemolysis and the Pathophysiology of Sickle Cell Disease.","volume":"127","author":"G Kato","year":"2017","journal-title":"J Clin Invest."},{"key":"ref-135","doi-asserted-by":"publisher","first-page":"893-902","DOI":"10.1001\/jama.2011.235","article-title":"Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis: A Randomized Controlled Trial.","volume":"305","author":"M Gladwin","year":"2011","journal-title":"JAMA."},{"key":"ref-136","doi-asserted-by":"publisher","first-page":"2121-9","DOI":"10.1007\/s00134-015-4060-2","article-title":"Inhaled Nitric Oxide for Acute Chest Syndrome in Adult Sickle Cell Patients: A Randomized Controlled Study.","volume":"41","author":"B Maitre","year":"2015","journal-title":"Intensive Care Med."},{"key":"ref-137","doi-asserted-by":"publisher","first-page":"1375-82","DOI":"10.3324\/haematol.2013.086637","article-title":"A Randomized, Placebo-Controlled Trial of Arginine Therapy for the Treatment of Children With Sickle Cell Disease Hospitalized With Vaso-Occlusive Pain Episodes.","volume":"98","author":"C Morris","year":"2013","journal-title":"Haematologica."},{"key":"ref-138","doi-asserted-by":"publisher","first-page":"4397150","DOI":"10.1155\/2019\/4397150","article-title":"Double-Blind Clinical Trial of Arginine Supplementation in the Treatment of Adult Patients With Sickle Cell Anaemia.","volume":"2019","author":"R Eleut\u00e9rio","year":"2019","journal-title":"Adv Hematol."},{"key":"ref-139","doi-asserted-by":"publisher","first-page":"855-64","DOI":"10.1182\/blood-2010-09-306167","article-title":"Hospitalization for Pain in Patients With Sickle Cell Disease Treated With Sildenafil for Elevated TRV and Low Exercise Capacity.","volume":"118","author":"R Machado","year":"2011","journal-title":"Blood."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/9-592\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-592\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-592\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T14:40:09Z","timestamp":1591886409000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/9-592\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":134,"URL":"https:\/\/doi.org\/10.12688\/f1000research.22433.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.24752.r64620","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.24752.r64619","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]},"assertion":[{"value":"Approved, Approved","URL":"https:\/\/f1000research.com\/articles\/9-592\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.24752.r64620, Daniel E. Bauer, Division of Hematology\/Oncology, Boston Children's Hospital, Boston, MA, USA, 11 Jun 2020, version 1, 2 approved","URL":"https:\/\/f1000research.com\/articles\/9-592\/v1#referee-response-64620","order":0,"name":"referee-response-64620","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.24752.r64619, Yogen Saunthararajah, Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA, 11 Jun 2020, version 1, 2 approved","URL":"https:\/\/f1000research.com\/articles\/9-592\/v1#referee-response-64619","order":1,"name":"referee-response-64619","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work is supported by an award from the US Food and Drug Administration - R01FD006030 (KIA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}